Viewing Study NCT04373369


Ignite Creation Date: 2025-12-24 @ 10:55 PM
Ignite Modification Date: 2025-12-24 @ 10:55 PM
Study NCT ID: NCT04373369
Status: TERMINATED
Last Update Posted: 2025-11-03
First Post: 2020-04-30
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Sponsor: Washington University School of Medicine
Organization:

Study Overview

Official Title: A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
Status: TERMINATED
Status Verified Date: 2025-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Insufficient Funding/Staff
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of the study is to determine whether adding vorolanib to atezolizumab will improve the length of time that participants are cancer-free after receiving standard chemotherapy.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: